The Contract Research Organization (CRO) services market supports pharmaceutical, biotech, and medical device companies by providing outsourced services across the drug development lifecycle—from early-stage discovery and preclinical studies to clinical trials, regulatory support, and data analytics. This market is expanding as organizations seek to control costs, speed time-to-market, and access global patient populations. Technological integration—including digital platforms, AI-led data processing, and decentralized trials—is transforming CRO delivery models. With growing complexity in clinical study design and increasing specialization (e.g. in gene therapies or oncology), CROs are playing a critical role in advancing innovative therapies worldwide.
According to Fortune Business Insights, the global Contract Research Organization (CRO) services market size was valued at USD 85.54 billion in 2024. The market is projected to grow from USD 92.27 billion in 2025 to USD 175.53 billion by 2032, exhibiting a CAGR of 9.6% during the forecast period. North America led the CRO services market, accounting for a 50.19% share in 2024.
In February 2024, Ergomed Group strengthened its geographic footprint by opening a new office in Kendall Square, Cambridge, Massachusetts—enhancing its ability to partner with U.S.-based sponsors.